Android
Zerodha Broker (Free Delivery)

India's No. 1 Broker with Best Software Trade @ Flat Rs 20

Open Instant Account
market update arrow Vehicle scrapping rules allow single window clearance for setting up ATSes arrow Coronavirus LIVE: India records 29,616 fresh cases, active cases rise arrow PM Modi raises issue of H-1B visas during first-ever meeting with Joe Biden arrow 'Pak has history of supporting terrorists', India slams Imran Khan at UNGA arrow Huawei CFO leaves Canada after agreement with US over fraud charges arrow PM Narendra Modi reaches New York to address 76th UNGA session arrow Tesla starts judging owners it charged $10,000 for self-driving arrow China's top regulators ban crypto trading, sending bitcoin tumbling arrow France, Germany nominate WHO chief Tedros for a second term arrow Govt will mandate flex-fuel engines in vehicles in next 3-4 months: Gadkari arrow RBI permits lenders to sell fraud loans to ARCs, paves way for resolution arrow Five stocks drive Sensex from 50,000 to 60,000: Check details here arrow Structural bull-run in Indian stock market remains intact: Chris Wood arrow Indian economy on sustained path of revival: Finance Minister Sitharaman arrow Advance tax collection up 52% in September quarter, shows CBDT data arrow Global oil and gas investment will be 30% below pre-Covid level: ONGC arrow Aditya Birla AMC eyes Rs 20,500 cr valuation in Rs 2,768 cr IPO arrow Daikin to set up Rs 1,000-crore AC manufacturing plant in Andhra Pradesh arrow Daikin to set up Rs 1,000-crore AC manufacturing plant in Andhra Pradesh arrow Shilpa Medicare to make drug substance for Cadila's ZyCoV-D vaccine arrow Sensex sprints to 60,000: Latest 5,000-pt rally comes in record 28 sessions arrow Birlas fail to nominate directors on the board of MP Birla group companies

CIPLA LTD.967.65 -0.45 (-0.05%)

  • BSE: 500087
  • |
  • NSE: CIPLA
  • |
  • ISIN NO: INE059A01026
  • |
  • INDUSTRY: Pharmaceuticals
Price table
Date Open High Low Close Volume Delivery % 20-Day SMA 50-Day SMA 200-Day SMA
24-Sep-2021 969.60 983.40 960.45 967.65 1803409 41.79 949.25 934.30 883.05
23-Sep-2021 965.45 970.00 959.50 968.10 1297533 56.28 946.45 934.30 882.00
22-Sep-2021 952.25 974.25 951.65 963.50 2267730 54.09 943.70 934.10 880.95
21-Sep-2021 935.00 959.00 933.00 956.10 2438464 51.88 941.40 934.05 879.95
20-Sep-2021 953.00 953.00 929.80 938.10 2308294 66.33 938.50 933.95 878.90
17-Sep-2021 960.00 962.50 948.05 954.05 2006356 55.87 936.15 934.45 877.90
16-Sep-2021 954.50 964.80 950.20 954.00 3574908 55.52 933.90 934.75 876.75
Key Data
  • Market cap 76959.00 CR.
  • Book value 247.00
  • Stock P/E 29
  • Dividend Yield 0.52%
  • ROCE 17.90%
  • ROE 13.00%
  • Sales Growth (3Y) 0.00%
  • Face Value (3Y) 2.00
CIPLA Share Price:

CIPLA share is currently trading at 967.65 at the PE of 29.

The 52-week range of CIPLA share price is 706.50 ~ 997.00

CIPLA share has a current face value of ₹2.00/-

Profile

CIPLA

Cipla Limited or CIPLA

The Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated in 1935. And Khwaja Abdul Hamied is the founder of Cipla who gave the company all of his patent & proprietary formulas for several drugs and medicines, without charging any particular royalty. As on August 17, 1935, Cipla was also registered as a public limited company with an authorized capital of INR 6 lakhs.

The business of ... the company :

It mainly focuses on the development of new formulations and also contains a wide range of pharmaceutical products and even offers prescription drugs, bulk drugs, animal products, and pesticides. It also deals in different types of food and beverages, baked foods, detergents, oral hygiene products, room fresheners, and personal care products, and much more. Approximately 55% of its overall income from its certain operations comes from overseas as it has 5,500 registered products in different countries. The Cipla offers drugs which are used for the treatment of cancer, Alzheimer's, arthritis, Parkinson, cardiovascular, and much more. It also provides medicines that prevent the transmission of AIDS from a mother to a child. It also offers various The Company offers consulting services on the preparation of products and materials, conducts plant evaluation, and supplies the plant equipment. It has set up the two institutes which are named as Dr. K. A Hamied Institute and the Cipla Cancer Palliative Care & Training Centre as well. It has its presence across 170 countries worldwide with various manufacturing units being approved by the regulatory authorities such as USFDA, WHO–Canada and MHRA–the UK, many others. The Cipla became the first company outside the US and Europe to launch the CFC or free inhalers. And in 2007, Cipla also launched an oral emergency contraceptive pill under the brand name as I–Pill and also launched a breakthrough screening technology in India. Also, the No-Touch Breast Scan or NTBS was the first ever painless, non–invasive, and radiation-free breast scanning technique for the detection of breast cancer at its initial stage. Then in 2009, it launched some of the generic versions of anti-flu drugs named oseltamivir and zanamivir in the local market to treat H1N1 influenza, which was spreading across the globe and especially in India. Later in 2010, the Piramal Healthcare Limited announced the signing of a definitive agreement with the Cipla Limited to purchase all the intellectual property rights in India related to 'i–pill' for an aggregate consideration of INR 95 crore.

Some of the Achievements:

  1. The company also won the "Forbes Asia's Best under a Billion" in the list from the Forbes Magazine.
  2. The Cipla also won the Most Profitable Company overall among its other competitors. Under a Billion in the Region and the Top 200 Small and Mid-Size companies from the Forbes Magazine.

The Milestones:

  1. 1998– It launched the lamivudine and became one of the few companies in the world to offer all three component drugs of the retroviral combination therapy in which zidovudine and stavudine were already launched.
  1. 1999– Launches Nevirapine, an antiretroviral drug, used to prevent the transmission of AIDS from mother to child.
  1. 2000– Cipla became the first company, outside the USA and Europe to launch CFC–free inhalers, that too ten years before the deadline to phase out the use of CFC in medicinal products.
  1. 2002– Four state–of–the–art manufacturing facilities set up in Goa in a record time of fewer than twelve months.
  1. 2003– Launches TIOVA (Tiotropium bromide), a novel inhaled, and a long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for all the patients with the chronic obstructive pulmonary disease (COPD). Commissioned the second phase of manufacturing operations at Goa.
  1. 2005– Sets–up state–of–the–art facility for the manufacture of formulations at Baddi, Himachal Pradesh.
  1. 2007– Sets–up state–of–the–art facility for the manufacture of formulations at Sikkim.
  1. 2010– Sets up state–of–the–art facility for production of formulations at Indore.

Read More
Trend Analysis
  • Short Term Trend :
    Up
  • Medium Term Trend :
    Not Clear
  • Long Term Trend :
    Not Clear

Are you friends with trend?

There is a saying in stock market, "Trend is your best friend"

It means, a good trader doesn't place his money against the trend. Many new traders lose money because they are trying to catch trend reversals but seasoned traders wait for a clear trend to emerge before taking the trade in the direction of trend.

Day Technicals

What is Opening Range Breakout?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

NR7

What is NR7 trading strategy?

Narrow Range trading strategy or NR7 Trading strategy is a breakout based method which assumes that the price of security trends up or down after a brief consolidation in a narrow range.

Opening Price clues

How to use Opening Price Clues in your trades?

If the stock has same open and high after it has traded for some time, it implies there was a consistent selling pressure that didn't allow the stock to move higher from the opening price. Similarly, if the stock has same open and low price, it implies there was a consistent buying intent that kept the stock price above the opening price.

Day High Low Range
TIME LOWEST HIGHEST
10 AM - -
11 AM - -
12 PM - -
1 PM - -
2 PM - -
Japanese Candlestick Patterns
Candle Pattern 1 :Doji
Candle Pattern 2 : None
Candle Pattern 3 :None
Candlestick Price Action
Higher High Higher Low
Pivot Points
Name S4 S3 S2 S1 Pivot Points R1 R2 R3 R4
classic 934.37 944.87 955.37 961.73 965.87 972.23 976.37 986.87 997.37
woodie's 939.20 949.70 954.60 960.20 965.10 970.70 975.60 981.20 991.70
fibonacci - 955.37 959.38 961.86 965.87 969.88 972.36 976.37 -
camarilla 962.32 965.21 966.18 967.14 -- 969.06 970.02 970.99 973.88
Past Performance & Moving Averages
Day’s LOW HIGH RANGE SMA Stock PERFORMANCE Nifty PERFORMANCE
10 DAY
929.80
983.40
955.81 1.95 % 2.63 %
20 DAY
907.50
983.40
949.27 2.70 % 2.75 %
50 DAY
872.00
989.90
934.32 3.87 % 9.95 %
100 DAY
869.00
997.00
938.06 1.50 % 13.21 %
200 DAY
738.10
997.00
883.04 20.08 % 19.46 %
YTD
738.10
997.00
892.56 17.97 % 27.39 %
52 Week
706.50
997.00
859.08 21.59 % 25.31 %

Why are moving Averages important in technical Analysis?

An opening range breakout is breaking out of the day's range after a stock has moved for some time in a sideways trend. In technical terms, its a breakout from the support and resistance level in an upward or downward trend.

Gaps On Day Chart
Unfilled Gap Up On 2020-04-09
564.00 ~ 530.00 SUPPORT
Industry Growth Rate

In Last 1 Year the industry has grown by 9.06 %

In Last 5 Year the industry has grown by 6.15 %

Peer comparison

Sales

COMPANY NAME 2015 2016 2017 2018 2019 2020
CIPLA 11345.00 13790.00 14394.00 15156.00 16362.00 17132.00
SUNPHARMA 27392.00 28487.00 31578.00 26489.00 29066.00 32838.00
LUPIN 12770.00 14256.00 17367.00 15797.00 16718.00 15375.00
DRREDDY 15023.00 15568.00 14196.00 14281.00 15448.00 17517.00
AUROPHARMA 12103.00 13772.00 14910.00 16463.00 19564.00 23099.00
Total 78633.00 85873.00 92445.00 88186.00 97158.00 105961.00

Financial

LAST FISCAL CURRENT GROWTH 10 YEAR CAGR
S.NO. COMPANY NAME MARKET CAP CMP BOOK VALUE EPS STOCK P/E ROE ICR REVENUE NET PROFIT NPM REVENUE NET PROFIT REVENUE NET PROFIT
1 SUN PHARMACEUTICAL INDUSTRIES LTD. 184603.12 769.30 98.33 15.69 27.17 15.69 22.95% 32838.00 3765.00 11.47% 12.98% 41.28% 23.41% 10.79%
2 MARKSANS PHARMA LTD. 283832.58 69.15 11.85 2.86 7.08 2.85 21.33% 1134.00 117.00 10.32% 13.40% 53.95% 12.19% 0.00%
3 MOREPEN LABORATORIES LTD. 255917.50 56.85 6.43 0.75 19.67 0.38 34.50% 853.00 34.00 3.99% 10.92% 17.24% 15.16% 0.00%
4 NEULAND LABORATORIES LTD. 197081.86 1538.00 542.16 12.63 37.00 1.23 4.64% 763.00 16.00 2.10% 14.39% 0.00% 10.62% 0.00%
5 Gufic BioSciences Ltd. 151496.60 194.95 10.85 2.94 24.32 2.88 3.46% 358.00 23.00 6.42% 1.99% 4.55% 19.36% 36.83%
6 DIVI'S LABORATORIES LTD. 135565.40 5108.85 266.77 51.85 37.86 25.98 260.43% 5394.00 1377.00 25.53% 9.06% 1.77% 19.07% 15.01%
7 DR.REDDY'S LABORATORIES LTD. 79599.15 4791.15 852.69 121.92 25.70 24.41 25.28% 17517.00 2026.00 11.57% 13.39% 3.90% 9.56% 19.13%
8 RPG LIFE SCIENCES LTD. 41788.21 252.45 105.02 17.54 16.28 2.23 20.00% 376.00 29.00 7.71% 13.94% 163.64% 8.99% 10.18%
9 Gland Pharma Ltd 62902.13 3847.40 242.00 0.00 0.00 48.31 136.43% 2633.00 773.00 29.36% 28.82% 71.02% 0.00% 0.00%
10 SMS PHARMACEUTICALS LTD. 34236.68 40.25 42.07 3.73 11.38 4.00 6.67% 412.00 32.00 7.77% -11.40% -20.00% 0.00% 0.00%
11 CIPLA LTD. 77936.89 967.00 209.71 19.18 23.33 9.61 16.27% 17132.00 1547.00 9.03% 4.71% 1.24% 12.32% 3.63%
12 TORRENT PHARMACEUTICALS LTD. 52253.71 3086.45 323.66 60.55 33.05 12.06 4.81% 7939.00 1025.00 12.91% 3.47% 135.09% 15.46% 16.07%
13 PIRAMAL ENTERPRISES LTD. 62504.90 2771.20 823.58 1.07 1363.55 0.53 1.18% 13068.00 24.00 0.18% -1.11% -98.37% 13.68% -25.92%
14 LUPIN LTD. 41968.08 926.20 384.76 -5.95 0.00 -2.96 6.19% 15375.00 -269.00 -1.75% -8.03% -144.32% 12.41% NaN
15 NECTAR LIFESCIENCES LTD. 66342.33 29.60 49.89 1.42 9.79 1.45 1.75% 2363.00 32.00 1.35% -14.97% -33.33% 10.86% -10.02%
16 AUROBINDO PHARMA LTD. 42289.76 722.10 206.07 48.32 10.51 47.98 15.90% 23099.00 2831.00 12.26% 18.07% 19.70% 20.72% 17.53%
17 Alkem Laboratories Ltd 48042.32 4001.85 501.34 94.26 25.32 46.96 22.66% 8344.00 1127.00 13.51% 13.42% 48.09% 0.00% 0.00%
18 ABBOTT INDIA LTD. 45202.89 21199.95 1004.00 279.04 46.86 28.24 84.11% 4093.00 593.00 14.49% 11.25% 31.78% 0.00% 0.00%
19 CADILA HEALTHCARE LTD. 57838.80 564.75 90.85 11.49 23.64 11.54 8.04% 14253.00 1177.00 8.26% 8.26% -36.34% 14.84% 8.83%
20 GLAXOSMITHKLINE PHARMACEUTICALS LTD. 25365.43 1497.65 138.61 5.50 250.36 0.55 18.00% 3224.00 93.00 2.88% 3.07% -79.10% 0.00% 0.00%
Sales

What is Sales Trend ?

Sales trend is a methodology to understand sales results which helps in understanding the trends of the market over a specific period of time. Sales results are an indicative of the sales patterns followed by the customer over a time period.

Profitability
Net Profit
EPS

What is EBITDA Margin & EBIT Margin ?

Corporate accounting is required to adhere to the standards and practices collectively referred to as the generally accepted accounting principles. EBITDA is an excellent way for corporate accountants to start compiling data, but it should not be considered an absolute result. This is due to the fact that many consider EBITDA more of a broad stroke than a definitive form of accounting practice.

EBITDA Margin
EBIT Margin
NPM
Cash Flow

Why is the Cash Flow Analysis important?

A business needs cash to pay its expenses, to pay bank loans, to pay taxes and to purchase new assets. A cash flow report determines whether a business has enough cash to do exactly this.

Operating Activities
Financing Activities
Investing Activities
Financial Health

What Is Financial Health?

Financial health is a term used to describe the state of one's personal monetary affairs. There are many dimensions to financial health, including the amount of savings you have, how much you’re putting away for retirement, and how much of your income you are spending on fixed or non-discretionary expenses.

Debt to Equity
Piotroski Score
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

What Is the Piotroski Score?

The Piotroski score is a discrete score between 0-9 that reflects nine criteria used to determine the strength of a firm's financial position.

Altman Z Score (Mfg Company)
  • Distress (< 1.81)
  • Caution (>1.81 < 2.99)
  • 4.30
    Safe (3 & above)
Altman Z Score (Non-Mfg Company)
  • Distress ( < 1.23)
  • Caution (>1.23 < 2.6)
  • 7.97
    Safe (2.6 & above)
Valuation

What Is Valuation?

Valuation is the analytical process of determining the current (or projected) worth of an asset or a company. There are many techniques used for doing a valuation. An analyst placing a value on a company looks at the business's management, the composition of its capital structure, the prospect of future earnings, and the market value of its assets, among other metrics.

CIPLA: Future
TRADING SYMBOL OI VOLUME LAST PRICE LOT SIZE EXPIRY DATE
CIPLA21SEPFUT 10217350.00 2715700.00 969.05 650.0 2021-09-30
CIPLA21OCTFUT 995800.00 1095250.00 972.00 650.0 2021-10-28
CIPLA21NOVFUT 22100.00 14950.00 970.70 650.0 2021-11-25
ROLLOVER COST: 0.30% (INR 2.95)
ROLLOVER%:9.06%
What is the significance of Rollover data?

Rollover in an important data point and should be analyzed in the expiry week. Rollover involves carry forwarding of ‘futures’ positions from one series (which is nearing expiry date) to the next one.

Rollover percentage actually indicates whether the traders are willing to carry forward their existing. positions (long or short) to the next series or not. Generally, the rollover figures alone will not indicate which direction traders are betting on. You should also check whether absolute open interest is increasing or decreasing over expiries

What is Options Max Pain Theory?

Options Max Pain Theory suggests,

“On option expiration day, the underlying stock price often moves toward a point that brings maximum loss to option buyers.”

Bulk Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
Block Deals
Symbol Name Deal Date Client Name Transcation Type Quantity Price
CIPLA 2019-04-01 HENDERSON EMG MKTS OPPORTUNITIES FUND A SERIES OF HENDERSON GLOBAL FUNDS S 249822.00 530.00
CIPLA 2019-04-01 HENDERSON GLOBAL TECHNOLOGY FUND A SERIES OF HENDERSON GLOBAL FUNDS S 1049182.00 530.00
CIPLA 2019-04-01 JANUS HENDERSON INTERNATIONAL OPPORTUNITIES FUND P 1299004.00 530.00
CIPLA 2019-03-25 HENDERSON EMG MKTS OPPORTUNITIES FUND A SERIES OF HENDERSON GLOBAL FUNDS S 249821.00 530.00
CIPLA 2019-03-25 HENDERSON GLOBAL TECHNOLOGY FUND A SERIES OF HENDERSON GLOBAL FUNDS S 1049181.00 530.00
CIPLA 2019-03-25 JANUS HENDERSON GLOBAL SUSTAINABLE EQUITY FUND P 1299002.00 530.00
CIPLA 2019-03-22 Y K HAMIED S 2775000.00 532.00
CIPLA 2019-03-22 MN RAJKUMAR GARMENTS LLP P 2775000.00 532.00
CIPLA 2018-06-05 HAMSONS LABORATORIES LLP S 492602.00 520.00
CIPLA 2018-06-05 M HAMIED P 2434970.00 520.00
CIPLA 2018-06-05 M HAMIED P 492602.00 520.00
CIPLA 2018-06-05 SHREE RIDDHI CHEMICALS LLP S 2434970.00 520.00
CIPLA 2018-01-25 SAGA CHEMICALS LLP S 232500.00 617.00
CIPLA 2018-01-25 SAGA CHEMICALS LLP S 232500.00 617.00
CIPLA 2018-01-25 GSA LULLA FAMILY PRIVATE TRUST P 232500.00 617.00
CIPLA 2018-01-25 ASK FAMILY PRIVATE TRUST P 232500.00 617.00
CIPLA 2017-10-27 MERRILL LYNCH MARKETS SINGAPORE PTE. LTD. P 86381.00 620.00
CIPLA 2017-10-27 MERRILL LYNCH CAPITAL MARKETS ESPANA SA SV S 86381.00 620.00
CIPLA 2010-01-14 SWISS FINANCE CORPORATION (MAURITIUS) LTD P 148470.00 343.00
CIPLA 2010-01-14 CITIGROUP GLOBAL MARKETS MAURITIUS PRIVATE LIMITED S 148470.00 343.00
CIPLA 2010-01-13 CREDIT SUISSE (SINGAPORE) LIMITED A/C CREDIT SUISSE (SINGAPO P 148470.00 341.00
CIPLA 2010-01-13 CITIGROUP GLOBAL MARKETS MAURITIUS PRIVATE LIMITED S 148470.00 341.00
Dividend history
Bonus Data
Company Name Split Date From Value To Value
No Data Found.
Split Data
Company Name Split Date From Value To Value
No Data Found.